Key result
PeV-A3 infection of human brain organoids elicited a significantly stronger inflammatory immune response (including IFN-λ1 and CXCL10) compared to PeV-A1, despite similar cell tropism.
Why the study?
Factors determining differential clinical outcomes between Parechovirus A genotypes—where PeV-A1 causes mild symptoms and PeV-A3 can elicit severe neurological disease—are poorly understood.
Genotype-specific immune responses, rather than differences in neuro-infectivity, may explain the severe clinical neuropathology associated with Parechovirus A3 compared to A1.
Answers are grounded in this paper and cite their sources.
May explain PeV-A3 neuropathology via genotype-specific inflammation; leaves open targeted interventions in infants.
Parechovirus A (PeV-A) is a species in the Picornaviridae family that can cause a variety of diseases, mainly in children.The most prevalent genotype, PeV-A1, can causes mild respiratory and gastrointestinal symptoms while the second most prevalent genotype, PeV-A3 can elicit severe neurological disease such as meningoencephalitis in infants. The factors determining differential outcomes between genotypes are poorly understood. In this study, we investigated the viral dynamics and tropism of PeV-A1 and PeV-A3 infection in human induced pluripotent stem cell (hiPSC)-derived unguided neural organoids (UNOs). UNOs supported PeV-A1 and PeV-A3 replication, as measured by RT-qPCR and confirmed by TCID50. Both genotypes showed similar cell tropism and infected neurons and astrocytes. Despite replicating up to a higher titre as compared to PeV-A3, PeV-A1 infection showed no significant cytokine upregulation while PeV-A3 infection resulted in an increased production of IFN-λ1 and CXCL10. This effect was also seen for Echovirus 11, another picornaviruses resulting in neurological disease. Blocking the IFN-pathway with Ruxolitinib resulted in enhanced replication of PeV-A3 indicating IFN-mediated restriction of PeV-A3 replication. This genotype-specific immune response could explain the exacerbated PeV-A3 associated severe clinical neuropathology.
No takes yet. Share an insight, caveat, or question.
Capendale et al. (2023) studied Parechovirus A infection (in vitro model). Parechovirus A3 (PeV-A3) infection vs. Parechovirus A1 (PeV-A1) infection and mock infection was evaluated on Viral replication kinetics, cell tropism, and cytokine expression (IFN-λ1, CXCL10). PeV-A3 infection of human brain organoids elicited a significantly stronger inflammatory immune response (including IFN-λ1 and CXCL10) compared to PeV-A1, despite similar cell tropism.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: